0.5 mg ranibizumab

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)NCT04757610Opthea LimitedPhase 3Terminated2025-03-31Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.